Clinical Trials Browser

Phase 3 × Alpelisib × Clear all

NCT05038735 2026-04-08

EPIK-B5

Phase 3 Active not recruiting

Breast Neoplasms

NCT04251533 2026-04-03

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Triple Negative Breast Neoplasms

NCT04208178 2026-04-02

EPIK-B2

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

Ovarian Neoplasms

NCT05501886 2026-02-10

VIKTORIA-1

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05646862 2026-02-05

INAVO121

Phase 3 Active not recruiting

Breast Neoplasms

NCT05063786 2025-09-08

ALPHABET

Phase 3 Active not recruiting

Breast Neoplasms

NCT02437318 2025-02-13

SOLAR-1

Phase 3 Completed

572 enrolled 22 charts 2 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT03439046 2024-08-01

BioItaLEE

Phase 3 Completed

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies